Business Wire

Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen

Jaa

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 3 study (Study 1961) of 470 virologically suppressed adult women with HIV infection, evaluating the efficacy and safety of switching from a boosted protease inhibitor (bPI) or boosted elvitegravir-containing regimen to Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg), a once-daily single tablet regimen. In the ongoing study, Biktarvy was found to be statistically non-inferior to regimens containing a bPI or boosted elvitegravir and demonstrated no treatment-emergent resistance at 48 weeks. The data were presented at the International Workshop on HIV and Women and at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston (Poster 2539).

“In this study, women who switched to Biktarvy maintained high levels of viral suppression, comparable to those who remained on a baseline regimen of either Genvoya®, Stribild® or ATV+RTV+FTC/TDF, and none of the participants on Biktarvy developed treatment-emergent resistance,” said Cissy Kityo, MD, Deputy Executive Director of Joint Clinical Research Centre, Kampala, Uganda and lead investigator on the study. “Conducting this women-only study on an international scale helps to further demonstrate that Biktarvy may be appropriate for a wide range of people living with HIV.”

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least three months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. No dosage adjustment of Biktarvy is required in patients with estimated creatinine clearance greater than or equal to 30 mL per minute. Biktarvy has a Boxed Warning in its product label regarding the risk of post treatment acute exacerbation of hepatitis B. See below for Important Safety Information.

In Study 1961, a total of 470 virologically suppressed adult women taking a regimen of atazanavir (ATV) + ritonavir (RTV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Stribild (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) or Genvoya (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) were randomized 1:1 to switch to open-label Biktarvy or stay on their baseline regimen (SBR). At Week 48, the primary endpoint of the study, switching to Biktarvy was non-inferior to continuing an SBR with 1.7 percent of participants in both the Biktarvy and the SBR arms having HIV-1 RNA ≥50 c/mL (difference 0.0 percent; 95 percent CI: -2.9 percent to 2.9 percent, p=1.00); the proportion of patients with HIV-1 RNA <50 c/mL was 95.7 percent in the Biktarvy arm and 95.3 percent in the SBR arm, according to FDA snapshot algorithm.

No patients in the Biktarvy treatment arm developed treatment-emergent resistance, while one patient taking Genvoya in the SBR arm developed an emergent M184M/I/V mutation. No renal adverse events leading to discontinuations and no cases of proximal renal tubulopathy occurred in either arm. The most commonly reported adverse events (all grades) in both arms included nasopharyngitis, upper respiratory tract infection, headache, vulvovaginal candidiasis and urinary tract infection. No patient in either treatment group discontinued the study due to an adverse event.

Demographic and baseline characteristics of the study participants were balanced with 37 percent Black, 28 percent white, 22 percent Asian and 16 percent Hispanic or Latina, a median age of 39 years and a median CD4 count of 686 cells/µL. Participants were recruited in the Dominican Republic, Russia, Thailand, Uganda and the United States.

“Gilead is committed to researching and developing treatments that have the potential to be used in a broad range of patients, including women who have traditionally been underrepresented in HIV clinical trials,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “This study demonstrates that Biktarvy offers a safety and efficacy profile that may help to care for women living with HIV.”

Additional clinical trials of Biktarvy are ongoing, including a study in adolescents and children living with HIV. Biktarvy is only approved for use in adults.

Biktarvy was approved by the United States Food and Drug Administration (FDA) on February 7, 2018. A marketing authorization application for Biktarvy is under review in the European Union.

Biktarvy does not cure HIV infection or AIDS.

Further information about the clinical study can be found at www.clinicaltrials.gov.

Important U.S. Safety Information for Biktarvy

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

  • Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of Biktarvy. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue Biktarvy. If appropriate, anti-hepatitis B therapy may be warranted.

Contraindications

  • Coadministration: Do not use Biktarvy with dofetilide or rifampin.

Warnings and precautions

  • Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during Biktarvy therapy and monitor for adverse reactions.
  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
  • New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of Biktarvy, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not initiate Biktarvy in patients with estimated creatinine clearance (CrCl) <30 mL/min. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue Biktarvy in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
    Renal monitoring: Prior to or when initiating Biktarvy and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, also assess serum phosphorus.
  • Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue Biktarvy if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse reactions

  • Most common adverse reactions (incidence ≥5%; all grades) in clinical studies were diarrhea (6%), nausea (5%), and headache (5%).

Drug interactions

  • Prescribing information: Consult the full prescribing information for Biktarvy for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
  • Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of Biktarvy. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of Biktarvy. Biktarvy can increase the concentration of drugs that are substrates of OCT2 or MATE1.
  • Drugs affecting renal function: Coadministration of Biktarvy with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions.

Dosage and administration

  • Dosage: 1 tablet taken once daily with or without food.
  • Renal impairment: Not recommended in patients with CrCl <30 mL/min.
  • Hepatic impairment: Not recommended in patients with severe hepatic impairment.
  • Prior to or when initiating: Test patients for HBV infection.
  • Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus.

Pregnancy and lactation

  • Pregnancy: There is insufficient human data on the use of Biktarvy during pregnancy. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population.
  • Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 10 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that physicians may not see the benefits of prescribing Biktarvy. In addition, the European Union and other regulatory authorities may not approve Biktarvy in the currently anticipated timelines or at all, and any marketing approvals, if granted, may have significant limitations on their use. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. full prescribing information for Biktarvy, Stribild and Genvoya, including BOXED WARNINGS, are available at  www.gilead.com .

Biktarvy, Stribild and Genvoya are trademarks of Gilead Sciences, Inc., or its related companies.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Investors
or
Ryan McKeel, 650-377-3548
Media

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Reorg Acquires Majority Stake in Debt Explained19.10.2018 11:00Tiedote

Reorg, a leading financial media and technology company, today announced it has acquired a controlling stake in London-based Debt Explained Limited, the leading provider of data and analysis on the European high-yield and leverage loan markets. Founded in 2009, Debt Explained creates and curates data and analysis on bond and loan deals through its proprietary data bases and unique scoring and bench-marking products. These allow for detailed trend analysis in the European high yield and leverage loan markets. The combination of Reorg and Debt Explained will make these tools available on a global basis, driving a new and unique subscriber experience in Europe, the United States and beyond. “Reorg’s partnership with Debt Explained will create the industry-leading product in the global non-investment grade credit markets,” said Kent Collier, founder and chief executive officer of Reorg. “This fits in perfectly with our strategic vision, and we look forward to building our business together

MapleStory 2 Hits 1 Million Account Downloads18.10.2018 23:43Tiedote

MapleStory 2, the newest leading free to play MMORPG in the illustrious and vibrant setting of Maple World, has officially hit 1 million account downloads, only a week after its launch. MapleStory 2 is available for download globally on Nexon Launcher and Steam. Since its official launch, MapleStory 2 has become one of the biggest MMORPGs on Steam and a beloved game for 1 million players due to its unlimited customization, quests, and its fun community. Due to its rapid growth, the game continues to increase its servers, especially the Oceania server, where player population continues to exceed expectations. To celebrate the occasion, MapleStory 2 will hold various events to commemorate the achievement and thank its players. MapleStory 2 1 Million Player Celebration Events: Double Bonus Item Drop Event: Starting Friday, Oct. 19 and going until Friday, Oct. 26, players will be able to earn double bonus items from normal adventure dungeons. Special Weekend Login Event: Beginning Saturday

Kristen Lisanti Joins BCW as Chief Culture Officer18.10.2018 20:17Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Kristen Lisanti has joined the firm as Chief Culture Officer, responsible for establishing an engaging culture at BCW that honors the diversity of its people and connects them through deep values, a global passion for the agency’s business and a fresh, new approach to employee satisfaction. In addition to driving employee engagement and building a global training program, Lisanti, based in New York, will be charged with establishing BCW as a best place to work around the world. “The culture of any organization is a critical pillar to its success,” said Donna Imperato, Global CEO, BCW, to whom Lisanti reports. “I’ve always focused on creating and nurturing the right culture. It doesn’t happen by itself and it requires just as much attention as other business aspects of an organization. BCW will be among the first in our industry to hire a global Chief Culture Officer whose sole focus will be to ensur

Limelight Networks and Ericsson to Accelerate Content Delivery and Edge Cloud Adoption18.10.2018 18:00Tiedote

Limelight Networks (NASDAQ: LLNW) and Ericsson (NASDAQ: ERIC) have signed an agreement to collaborate on content delivery and edge cloud services. As more traffic shifts to the public internet from private networks, the need for high performance networks and distributed infrastructure is required to maintain a high-quality user experience. A key solution to this is edge cloud computing. Providing computing capabilities close to the user or device gives a superior quality of service. For new low latency applications such as IoT, gaming, and virtual reality, robust computing capabilities at the edge of the network are needed. Communications service providers and technology companies will play a pivotal role in scaling the next wave of internet traffic. Ericsson is partnering with service providers globally to build the Ericsson Unified Delivery Network (UDN) Edge Cloud Platform – a web-scale edge delivery network, driving performance benefits and cost efficiencies. Content delivery is th

World Leader in High-End Mobile Security, Kaymera Technologies, to Expand Adaptive Mobile Threat Defense Footprint18.10.2018 16:56Tiedote

Kaymera Technologies, the leader in high-end Mobile Threat Defense solutions, today announced that BGŻ BNP Paribas have chosen the Kaymera’s Adaptive Mobile Threat Defense Platform to help protect personal and business-related mobile data across its employee base and business partners. According to a recent reports survey of IT Security professionals on Bring Your Own Device (BYOD), one in five organizations has suffered a mobile security breach, primarily driven by malware and malicious WiFi. 24% of organizations confirmed their mobile devices have connected to malicious WiFi networks while 48% were unsure if there have been any mobile security incidents. With at least one device in every large organization likely infected with malware, and one-third of executives experiencing network attacks, most enterprises are looking for a strong defense system against mobile threats. “We were looking for solutions to further increase mobility across our organization by boosting our mobile securi

Piraeus Bank Signs Financing Agreement of €40 million with Thomas Cook Hotel Investments18.10.2018 16:18Tiedote

Piraeus Bank signed a financing agreement of €40 million with Thomas Cook Hotel Investments (TCHI), a joint venture between Thomas Cook plc and LMEY Investments AG. Piraeus Bank is the sole financial partner of TCHI in Greece and the financing will be used to invest in local hotel properties. Thomas Cook Hotel Investments was established in March 2018 to support the growth of Thomas Cook’s own-brand hotels in Spain and Greece. The portfolio of TCHI includes owned hotel properties in Rhodes and Crete under the brand of Sunwing. Thomas Cook Group is one of the world’s leading leisure travel groups, with sales of £9 billion in the year ended 30 September 2017, serving over 20 million customers annually. Thomas Cook was the biggest international tour operator in Greece this year, while it served 3 million customers. Funding of tourism, a vital sector for the Greek economy, is a key priority for Piraeus Bank. With a tourism portfolio in excess of €2 billion, the Bank supports tourism busine

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme